Post-finasteride syndrome: pharmacists must lead the conversation on patient safety

In 2025, the European Medicines Agency (EMA) confirmed what patient advocacy groups had been warning about for more than a decade: finasteride, a 5-alpha reductase inhibitor prescribed to millions of men for androgenetic alopecia, is associated with suicidal ideation^​1​. The same year, the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare products Regulatory Agency (MHRA) took steps to strengthen label warnings^​2,3​. Yet, despite these regulatory signals, awareness among pharmacy teams remains alarmingly low, based on the experiences reported by patients. As healthcare professionals most accessible to the public, pharmacists are uniquely placed to protect patients from the devastating consequences of this medication, but only if they understand what is at stake.

Post-finasteride syndrome (PFS) is a characterised by persistent sexual, neuropsychiatric and physical dysfunction that emerges upon cessation of finasteride and, crucially, does not resolve^​4​. The symptom profile extends far beyond the sexual side effects listed on current product information. SIDEfxHUB is a UK charity that funds PFS research, raises awareness and supports people living with the debilitating condition. Patients in the SIDEfxHUB registry — which now includes more than 521 individuals in the UK — commonly report severe insomnia, complete emotional blunting (i.e. anhedonia), cognitive impairment, muscle wasting, joint pain, tinnitus, visual disturbances, genital tissue changes and gastrointestinal dysfunction^​5​.

The literature suggests that finasteride disrupts not only the conversion of testosterone to dihydrotestosterone but also the metabolism of neurosteroids, including allopregnanolone, which are critical for emotional regulation, cognition, memory and sleep^​6​. Emerging research points to epigenetic adaptation to the low-androgen environment created by finasteride; in genetically susceptible individuals, these changes may become irreversible upon drug withdrawal^​7,8​.

One of the most pressing concerns for pharmacy practice is the inadequacy of screening. Patients are routinely asked whether they have a prior history of mental health problems, with a negative answer treated as a green light to proceed. The vast majority of PFS patients supported by SIDEfxHUB are young, healthy men with no psychiatric history whatsoever. The underlying mechanisms of PFS are not yet fully understood and no validated screening tool exists to identify who is at risk^​9​. The current approach is therefore ineffective and potentially harmful, because it provides both prescriber and patient with a false sense of security that is not grounded in evidence.

At present, the UK approach is not aligned with the precautionary measures being adopted elsewhere in Europe. In France, the Agence Nationale de Sécurité du Médicament (ANSM) has introduced a mandatory risk acknowledgement process, requiring both the prescriber and patient to complete and sign a detailed consent form outlining the full spectrum of adverse effects — including psychiatric symptoms, sexual dysfunction and the potential for persistence after discontinuation^​10​. This discussion must take place during an in-person consultation. In Belgium, regulators have taken a more rigorous fundamental position. Historically, they have declined to grant marketing authorisation for finasteride for cosmetic indications on the basis that its risk-benefit profile is unacceptable in that context¹³.

Meanwhile, use of finasteride is increasingly widespread. Since the expiry of the drug’s patent in 2014, prescribing volumes in the UK have risen substantially, reaching more than 4.5 million prescriptions in 2025^​11​. This growth has been driven in part by the scalability of online prescribing models and social media advertising. Pharmacists are therefore not peripheral actors in this system — they are central to it.

The human cost of the gap in awareness is stark. In one week in early 2026, three families contacted SIDEfxHUB for support after their young, otherwise healthy adult child had died by suicide, either shortly after starting finasteride or following cessation. Because coroners are largely unaware of the causal pathway between finasteride and suicidality, these deaths are rarely recorded as drug related. Families are left fighting to have finasteride even mentioned during inquests, despite suicide notes that describe PFS symptoms in harrowing detail. The EMA’s 2025 review identified 325 cases of suicidal ideation linked to finasteride in young men treated for hair loss, based on all EudraVigilance reports on record at the time^​1​.

Equally concerning is the treatment pathway that follows diagnosis. When PFS patients present to their GP with neuropsychiatric symptoms, such as depression or anxiety, the reflex response is often to prescribe a selective serotonin reuptake inhibitor (SSRI). Our experience as a charity is that this is the single most dangerous intervention for this patient group. Whatever predisposes an individual to PFS appears also to predispose them to post-SSRI sexual dysfunction (PSSD), a condition with a near-identical symptom profile^​12​. Research from the University of Milan, Italy, has identified shared pathological mechanisms between the two conditions, including neurosteroid depletion, epigenetic modifications and gut–brain axis disruption^​13​. Pharmacists dispensing SSRIs to patients with a history of finasteride use should, at a minimum, be aware of this risk.

This raises an uncomfortable question that the profession must confront: does a medication prescribed for a cosmetic indication carry an acceptable risk–benefit profile if it causes a subset of patients to take their own lives? Both the EMA and FDA have formally acknowledged the link between finasteride and suicidality^​1,2​. We would not accept a tooth-whitening procedure or cosmetic surgery procedure that carried a risk of suicide, persistent sexual dysfunction and irreversible neurological harm. Why is it being accepted here?

Pharmacists and pharmacy teams are often one of the last healthcare professionals a patient will encounter before starting finasteride. This places them in a position of enormous responsibility. It must be ensured that patients receive meaningful counselling that goes beyond the current inadequate checklist. Counselling must include the full breadth of reported persistent adverse effects, the absence of reliable risk prediction and the regulatory warnings that are now in place. We must also ensure that colleagues across the profession are equipped to recognise PFS when it presents and to consider the risks of prescribing SSRIs that may catastrophically worsen the condition. Patient safety demands nothing less.